EW Edwards Lifesciences Corp

Price (delayed)

$72.48

Market cap

$44.81B

P/E Ratio

30.97

Dividend/share

N/A

EPS

$2.34

Enterprise value

$44.25B

Edwards Lifesciences is an American medical technology company headquartered in Irvine, California, specializing in artificial heart valves and hemodynamic monitoring. It developed the SAPIEN transcatheter aortic heart valve made of ...

Highlights
The price to earnings (P/E) is 38% lower than the 5-year quarterly average of 50.1 and 30% lower than the last 4 quarters average of 44.3
EW's quick ratio is up by 15% since the previous quarter and by 2.8% year-on-year

Key stats

What are the main financial stats of EW
Market
Shares outstanding
618.26M
Market cap
$44.81B
Enterprise value
$44.25B
Valuations
Price to earnings (P/E)
30.97
Price to book (P/B)
7.23
Price to sales (P/S)
8.38
EV/EBIT
25.92
EV/EBITDA
23.64
EV/Sales
8.25
Earnings
Revenue
$5.36B
EBIT
$1.71B
EBITDA
$1.87B
Free cash flow
$1.04B
Per share
EPS
$2.34
Free cash flow per share
$1.68
Book value per share
$10.03
Revenue per share
$8.65
TBVPS
$11.64
Balance sheet
Total assets
$8.64B
Total liabilities
$2.42B
Debt
$686.8M
Equity
$6.22B
Working capital
$2.6B
Liquidity
Debt to equity
0.11
Current ratio
3.83
Quick ratio
2.61
Net debt/EBITDA
-0.3
Margins
EBITDA margin
34.9%
Gross margin
78.9%
Net margin
27.2%
Operating margin
32.5%
Efficiency
Return on assets
17.2%
Return on equity
24.5%
Return on invested capital
30.2%
Return on capital employed
22.1%
Return on sales
31.8%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

EW stock price

How has the Edwards Lifesciences stock price performed over time
Intraday
-0.14%
1 week
-6.55%
1 month
4%
1 year
-39.33%
YTD
-44.05%
QTD
-12.28%

Financial performance

How have Edwards Lifesciences's revenue and profit performed over time
Revenue
$5.36B
Gross profit
$4.23B
Operating income
$1.74B
Net income
$1.46B
Gross margin
78.9%
Net margin
27.2%
The operating income has grown by 12% YoY
EW's gross profit is up by 10% year-on-year
The company's operating margin rose by 7% YoY
The net margin has contracted by 6% YoY

Growth

What is Edwards Lifesciences's growth rate over time

Valuation

What is Edwards Lifesciences stock price valuation
P/E
30.97
P/B
7.23
P/S
8.38
EV/EBIT
25.92
EV/EBITDA
23.64
EV/Sales
8.25
The price to earnings (P/E) is 38% lower than the 5-year quarterly average of 50.1 and 30% lower than the last 4 quarters average of 44.3
The stock's price to book (P/B) is 35% less than its last 4 quarters average of 11.2 and 34% less than its 5-year quarterly average of 11.0
The equity has grown by 12% year-on-year and by 4.6% since the previous quarter
The P/S is 32% below the last 4 quarters average of 12.4 and 22% below the 5-year quarterly average of 10.8
EW's revenue is up by 5% year-on-year

Efficiency

How efficient is Edwards Lifesciences business performance
The company's return on invested capital fell by 19% YoY and by 2.3% QoQ
Edwards Lifesciences's return on equity has decreased by 18% YoY and by 2.4% QoQ
EW's return on assets is down by 12% year-on-year
The company's return on sales fell by 5% YoY

Dividends

What is EW's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for EW.

Financial health

How did Edwards Lifesciences financials performed over time
EW's quick ratio is up by 15% since the previous quarter and by 2.8% year-on-year
The company's current ratio rose by 14% QoQ and by 5% YoY
The debt is 89% less than the equity
The equity has grown by 12% year-on-year and by 4.6% since the previous quarter
The company's debt to equity fell by 8% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.